Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Clinical and prognostic features of erionite-induced malignant mesothelioma.

Demirer E, Ghattas CF, Radwan MO, Elamin EM.

Yonsei Med J. 2015 Mar;56(2):311-23. doi: 10.3349/ymj.2015.56.2.311. Review.

2.

Health risk of chrysotile revisited.

Bernstein D, Dunnigan J, Hesterberg T, Brown R, Velasco JA, Barrera R, Hoskins J, Gibbs A.

Crit Rev Toxicol. 2013 Feb;43(2):154-83. doi: 10.3109/10408444.2012.756454. Review.

3.

Erionite exposure in North Dakota and Turkish villages with mesothelioma.

Carbone M, Baris YI, Bertino P, Brass B, Comertpay S, Dogan AU, Gaudino G, Jube S, Kanodia S, Partridge CR, Pass HI, Rivera ZS, Steele I, Tuncer M, Way S, Yang H, Miller A.

Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13618-23. doi: 10.1073/pnas.1105887108.

4.

Factors that impact susceptibility to fiber-induced health effects.

Below JE, Cox NJ, Fukagawa NK, Hirvonen A, Testa JR.

J Toxicol Environ Health B Crit Rev. 2011;14(1-4):246-66. doi: 10.1080/10937404.2011.556052.

5.

Applying definitions of "asbestos" to environmental and "low-dose" exposure levels and health effects, particularly malignant mesothelioma.

Case BW, Abraham JL, Meeker G, Pooley FD, Pinkerton KE.

J Toxicol Environ Health B Crit Rev. 2011;14(1-4):3-39. doi: 10.1080/10937404.2011.556045. Review.

6.

Malignant mesothelioma: facts, myths, and hypotheses.

Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, Gazdar AF, Pass HI, Yang H.

J Cell Physiol. 2012 Jan;227(1):44-58. doi: 10.1002/jcp.22724. Review.

Items per page

Supplemental Content

Support Center